DOCSLIB.ORG

2006 ESDR Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2006 ESDR Abstracts 2006 ESDR ABSTRACTS View metadata, citation and similar papers at core.ac.uk brought to you by CORE 001 [003] 004 [022] provided by Elsevier - Publisher Connector Functional Effects Of Pachyonychia Congenita Type I Mutations on Keratinocyte Migration P120-catenin is a New Member of Desmosome to Recruit desmoglein3 (Dsg3) to Desmosomes and the Actin Cytoskeleton by Binding to its Cytoplasmic Membrane-proximal Domain Van Koningsveld R1, Fitchett CJ1, Rugg EL2 and O’Toole EA1 Kanno M, Aoyama Y, Nagai M, Yamamoto Y and Kitajima Y 1Centre for Cutaneous Research, ICMS, Queen Mary, University of London (United Kingdom) Department of dermatology, Gifu University School of Medicine (Japan) 2Department of Dermatology, University of California, Irvine (USA) p120-catenin (p120-ctn) is armadillo family protein, which binds to classical cadherins at Keratins are the largest group of cytoskeletal proteins forming the intermediate fi lament cy- the juxtata membrane domain (JMD) of cytoplasmic domain through its arm repeat domain. toskeleton within epithelial cells. Keratins K6a and K16 are expressed in wound healing, skin Recently several lines of evidence indicate that p120-ctn stabilizes cadherins and regulates cancer and psoriasis and mutations in these genes cause type I pachyonychia congenita (PC1). the cell adhesion positively . We have already shown the association of endogeneous Dsg 1 The aim of this study was to investigate the effect of over-expression of wild-type or mutant K6a and 3 associated with p120ctn by immunoprecipitation study and the localization of p120- (K6aN171del) and K16 (K16R127C) on human keratinocyte (HK) migration, and study the sig- ctn at desmosome by immuno-electron microscopy. To investigate the association manner of nalling pathways involved. Phoenix cells (HEK293 cells modifi ed to express retroviral packag- Dsg3 and p120-ctn, we constructed expression vectors containing Flag tagged mutant forms of ing proteins) were transfected with target genes and the supernatant was used to infect primary mouse Dsg3 with increasing truncations eliminating various cytoplasmic subdomain from the HK. Migration was assessed using the colloidal gold and in vitro scratch assays. Expression of carboxy-terminus, which is ∆ICS:AA1-810, AA1-761,∆IA:AA1-714, 1-641, respectively. These signalling molecules was investigated using Western blotting and differentially expressed genes constructs and HA tagged mouse p120-ctn were co-transfected into HEK293 cell. Extracts using Afymmetrix chip technology. All cells migrated further in the presence of 10nM EGF, were subjected to immunoprecipitation with anti-HA antibody. Recoverd p120-ctn contained however, the K16R127C-transduced HKs displayed maximal hypermotility in response to EGF all Dsg3 mutants but not 1-641. The result suggests that the cytoplasmic membrane-proximal in the colloidal gold assay (p<0.0001). Both K16 and K16R127C-expressing cells displayed hy- domain including IA region (641-714AA) of Dsg3 is the binding site for p120-ctn. To confi rm permotility in the in vitro scratch assay. Maximal p38 phosphorylation in response to EGF was the role of p120-ctn, we generated another mutant form of mouse Dsg3, ∆641-714. We deter- seen in the K16R127C-transduced HKs. The K16R127C-transduced keratinocytes displayed mined the localization of these recombinant proteins in DJM-1 cells by immunofl uorescence. decreased basal expression of cofi lin, an actin-binding protein. Data-mining of the Afymmetrix P120-ctn was found to co-localize with ∆ICS:AA1-810, AA1-761, ∆IA:AA1-714, but neither chip data using Genespring identifi ed altered expression of several genes involved in actin ∆IA:AA1-641 nor AA641-714, immunocytochemicaly. Interestingly, ∆IA:AA1-641 and AA641- remodelling in the transduced cells suggesting that the PC type I mutation, R127C, signifi cantly 714 which lack the cytoplasmic membrane-proximal region, were localized in the cytoplasm alters keratinocyte migration by affecting actin cytoskeletal dynamics. These changes may play but not localized at the plasma membrane. These results suggest that p120-ctn can associate a role in the stress-induced clinical phenotype seen in PC1. not only with classical cadherin, but also with desmosomal cadherin as a new member of desmosomal constituents, and that p120-ctn might be involved in stabilization of Dsg3 at the 002 [011] plasma membrane. Serpin Squamous Cell Carcinoma Antigen-1 Suppresses UV-induced Cell Death In Vivo and In Vitro 005 [048] Hibino T, Katagiri C and Nakanishi J Novel Targets for Cystatin M/E: A New Route in Epidermal Differentiation Shiseido Life Science Research Center (Japan) Cheng T1, Hitomi K2, Ishida-Yamamoto A3, van Vlijmen-Willems IM1, de Jongh GJ1, Bergers M1, Schalkwijk J1 and Zeeuwen PL1 Recently we have demonstrated that serpin squamous cell carcinoma antigen 1 (SCCA1) plays 1Department of Dermatology, Radboud University Nijmegen Medical Centre (Netherlands) a critical role in UV-induced apoptosis in human keratinocytes. This reaction was mediated via 2Department of Applied Molecular Biosciences, Nagoya University (Japan) specifi c suppression of c-Jun N-terminal kinase-1 (JNK1). In the present study, we generated 3Department of Dermatology, Asahikawa Medical College (Japan) transgenic mice that overexpressed SCCA1 driven from the involucrin promoter and examined the effect of UV irradiation. In addition, we established various cell lines, in which SCCA1 was Cystatin M/E is a high affi nity inhibitor of the asparaginyl endopeptidase legumain. Although overexpressed or downregulated. Using these cell lines we further analyzed the roles of SCCA1 cystatin M/E also contains a predicted binding site for papain-like cysteine proteases, no high in cell death and proliferation. affi nity binding for any member of this family has been demonstrated so far. The present study Since SCCA1 was strongly upregulated in the upper epidermis of sun-exposed skin, we gener- aims on fi nding these unknown target proteins of cystatin M/E. Furthermore, we investigated ated involucrin promoter-driven SCCA1 transgenic mice. In order to obtain hairless phenotype, the possible role of cystatin M/E and its physiological target proteases in epidermal differentia- the involucrin-SCCA1 transgenic mice were crossed with HR-1 mice and SCCA1+/+ mice were tion and desquamation. We report that human cathepsin V (CTSV) and human cathepsin L obtained after three passages. Immunostaining of skin sections revealed strong expression of (CTSL) are strongly inhibited by human cystatin M/E. Kinetic studies show that Ki values of SCCA1 in the upper epidermis of the transgenic mice but not in the skin of wild HR-1 mice. cystatin M/E for the interaction with CTSV and CTSL are 0.47 nM and 1.78 nM, respectively. When 200 mJ/cm2 of UV was irradiated twice on the back of mice, the epidermis of wild Site-directed mutagenesis was used to identify the binding sites of cystatin M/E. We found that type mice was seriously damaged, showing spongiosis in the suprabasal layer. In contrast, the legumain and the papain-like cysteine proteases CTSV and CTSL are inhibited by two distinct mutant mice demonstrated remarkable resistance against UV irradiation. We transfected hu- non-overlapping sites. Localization studies in normal human skin show that cystatin M/E co- man SCCA1 cDNA into 3T3/J2 cells and established 20 individual clones that stably express localizes with CTSV and CTSL in the upper layers of the epidermis. Furthermore, we show that SCCA1. SCCA1-expressing clones showed a strong correlation between the expression levels CTSL is the elusive enzyme that processes and activates epidermal transglutaminase 3, an en- and the suppression of UV-induced apoptosis. In SCCA knockdown HaCaT cells using siRNA, zyme responsible for crosslinking during epidermal cornifi cation. Compartmentalization stud- UV-induced apoptosis dramatically increased. Interestingly downregualtion of SCCA1 resulted ies using immunoelectron microscopy revealed that both cystatin M/E and CTSV are found in in marked increase of phospho-c-Jun and UV irradiation further enhanced the levels of c-Jun the extracellular space in the stratum corneum associated with corneodesmosomes, suggesting phosphorylation. Our data suggest that the up-regulation of SCCA1 is enough to suppress UV- an important role for these molecules in epidermal desquamation. The identifi cation of CTSV induced apoptosis and reveal a novel UV protection mechanism in the human skin. and CTSL as novel targets for cystatin M/E, their co-expression in human skin, and the activity of CTSL towards transglutaminase 3, strongly implies an important role for these molecules in the differentiation process of human epidermis. 003 [021] Functional Study of the Dermokine σ, an Intracellular Isoform Encoded by an Epidermal Gene with a Complex Splicing 006 [049] Leclerc E, Jonca N, Toulza E, Gazeilles L, Serre G and Guerrin M The activity of PI3K-Akt-mTOR Survival Pathway in Keratinocytes is Critically Dependent on “Epidermal Differentiation and Rheumatoïd Autoimmunity”, UMR 5165 CNRS-Toulouse III the Integrity of Lipid Rafts in the Membrane University (France) Calay D and Gniadecki R Department of Dermatology, Bispebjerg Hospital, University of Copenhagen (Denmark) In order to better understand the molecular mechanism underlying the cohesion/desquama- tion processes which are essential for the barrier function, we have analyzed the granular Lipid rafts are nanometer-large, cholesterol- and shingolipid-rich plasma membrane microdo- keratinocyte transcriptome.
Load more

Recommended publications
  • WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT (51) International Patent Classification: (71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400 A 61K 35/1 7 (20 15.0 1) A 61P 35/00 (2006 .0 1) Dexter Ave. N., Suite 1200, Seattle, WA 98109 (US). (21) International Application Number: (72) Inventor: ALBERTSON, Tina; 400 Dexter Ave. N., Suite PCT/US2018/035755 1200, Seattle, WA 98109 (US). (22) International Filing Date: (74) Agent: AHN, Sejin et al; Morrison & Foerster LLP, 1253 1 0 1 June 2018 (01 .06.2018) High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/5 14,774 02 June 2017 (02.06.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/5 15,530 05 June 2017 (05.06.2017) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/521,366 16 June 2017 (16.06.2017) u s HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/527,000 29 June 2017 (29.06.2017) u s KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/549,938 24 August 2017 (24.08.2017) u s MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/580,425 0 1 November 2017 (01 .11.2017) u s OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/593,871 0 1 December 2017 (01 .12.2017) u s SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/596,764 08 December 2017 (08.12.2017) u s TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Annual Report 2011-12
    ANNUAL REPORT 2011-12 Creating a better future every day HINDUSTAN UNILEVER LIMITED Registered Office: Unilever House, B D Sawant Marg, Chakala, Andheri East, Mumbai 400099 Hindustan www.hul.co.in U nilever nilever L imited Annual Report 2011-12 AwARDS AND FELICITATIONS WINNING WITH BRANDS AND WINNING THROUGH CONTINUOUS SUSTAINABILITY OUR MISSION INNOVATION IMPROVEMENT HUL has won the Asian Centre for Six of our brands (Lux, Lifebuoy, Closeup, HUL was awarded the FMCG Supply Corporate Governance and Sustainability Fair & Lovely, Clinic Plus and Sunsilk) Chain Excellence Award at the 5th Awards in the category ‘Company with the featured in Top 15 list in Brand Equity’s Express, Logistics & Supply Chain Awards Best CSR and Sustainability Practices.’ WE WORK TO CREATE A BETTER FUTURE Most Trusted Brands Survey. endorsed by The Economic Times along Our instant Tea Factory, Etah bagged the with the Business India Group. EVERY DAY. Hindustan Unilever Limited (HUL) was second prize in tea category for Energy awarded the CNBC AWAAZ Storyboard Doomdooma factory won the Gold Award Conservation from Ministry of Power, We help people feel good, look good and get more out Consumer Awards 2011 in three in the Process Sector, Large Business Govt. of India. categories. category at The Economic Times India HUL won the prestigious ‘Golden Peacock Manufacturing Excellence Awards 2011. of life with brands and services that are good for them • FMCG Company of the Year Global Award for Corporate Social and good for others. • The Most Consumer Conscious Responsibility’ for the year 2011. Company of the Year WINNING WITH PEOPLE HUL’s Andheri campus received • The Digital Marketer of the Year We will inspire people to take small, everyday actions HUL was ranked the No.1 Employer of certification of LEED India Gold in ‘New HUL won the ‘Golden Peacock Innovative Choice for students in the annual Nielsen Construction’ category, by Indian Green that can add up to a big difference for the world.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Eisai Submits Marketing Authorization Application in Japan
    N o. 20-15 March 26, 2020 Eisai Co., Ltd. EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL). This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent. This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI：12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17). The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%). Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte.
    [Show full text]
  • WES Gene Package Multiple Congenital Anomalie.Xlsx
    Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar,
    [Show full text]
  • Vernieuwend Wassen R&D in Vlaardingen En De Detergents-Business Van Unilever
    Vernieuwend wassen: Vernieuwend Vernieuwend wassen Vernieuwend wassen R&D in Vlaardingen en de detergents-business van Unilever R&D in Vlaardingen en de detergents-business Met de vorming van Unilever in 1930 ontstond één van de grootste zeep- en margarine- R&D in Vlaardingen en de producenten ter wereld. Zeep en margarine vormen overigens een logische combinatie, van Unilever beide bedrijfstakken werkten immers met dezelfde grondstoffen: oliën en vetten. In dit cahier staat de Research & Development van Unilever op het terrein van wasmiddelen Ton van Helvoort, Mila Davids en Harry Lintsen centraal. Waar het bij de R&D van voedingsmiddelen vaak om stapsgewijze zogeheten onzichtbare innovaties gaat, wordt de markt van wasmiddelen juist gekenmerkt door een reeks van radicale innovaties. De meest cruciale nieuwigheid was het op de markt komen van de synthetische wasmiddelen. Niet langer vormden plantaardige of dierlijke grondstoffen de basis, de bouwstenen werden voortaan geleverd door de aardolie- industrie. detergents Om de positie op de markt te kunnen vasthouden stond aan wasmiddelen gerelateerd onderzoek bij de Unilever laboratoria in Port Sunlight (Engeland) en Vlaardingen hoog -business van Unilever op de agenda. Innovaties vonden zowel plaats in de processing als in het verbeteren van de wasmiddelen. De auteurs laten zien hoe de onderzoekers van Unilever zich richtten op onderwerpen zoals de werking van oppervlakactieve stoffen, de toepassing van enzymen, fosfaatverontreiniging, het bleken bij lage temperatuur en de bijbehorende vermindering van het energieverbruik alsmede de bereiding van compacte poeders. De analyse van de R&D-inspanningen maakt duidelijk hoe allerlei ontwikkelingen met elkaar samenhangen; elke ‘innovatieve’ aanpassing kan gevolgen hebben elders in het netwerk.
    [Show full text]
  • A Bispecific Enediyne-Energized Fusion Protein Targeting Both Epidermal Growth Factor Receptor and Insulin-Like Growth Factor 1
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 16), pp: 27286-27299 Research Paper A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non- small cell lung cancer Xiao-Fang Guo1, Xiao-Fei Zhu2,3, Hai-Ying Cao1, Gen-Shen Zhong4, Liang Li5, Bao-Guo Deng1, Ping Chen1, Pei-Zhen Wang1, Qing-Fang Miao5, Yong-Su Zhen5 1Department of Microbiology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China 2Department of Clinical Immunology, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, China 3Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang, China 4Laboratory of Cancer Biotherapy, Institute of Neurology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China 5Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Perking Union Medical College, Beijing, China Correspondence to: Xiao-Fang Guo, email: [email protected] Yong-Su Zhen, email: [email protected] Keywords: EGFR, IGF-1R, lidamycin, bispecific fusion protein, NSCLC Received: July 04, 2016 Accepted: February 20, 2017 Published: March 06, 2017 Copyright: Guo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited ABSTRACT Epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF-1R) both overexpressed on non-small cell lung cancer (NSCLC) and are known cooperatively to promote tumor progression and drug resistance. This study was to construct a novel bispecific fusion protein EGF-IGF-LDP-AE consisting of EGFR and IGF-IR specific ligands (EGF and IGF-1) and lidamycin, an enediyne antibiotic with potent antitumor activity, and investigate its antitumor efficacy against NSCLC.
    [Show full text]
  • A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin
    Title: A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T- Cell Lymphoma NCT Number: NCT01578499 Protocol Approve Date: 02 December 2014 Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from view with a black/blue bar) to protect either personally identifiable information (PPD) or company confidential information (CCI). This may include, but is not limited to, redaction of the following: Named persons or organizations associated with the study. Proprietary information, such as scales or coding systems, which are considered confidential information under prior agreements with license holder. • Other information as needed to protect confidentiality of Takeda or partners, personal information, or to otherwise protect the integrity of the clinical study. Brentuximab vedotin (SGN-35) Clinical Study Protocol C25001 Amendment 5, EudraCT: 2010-024215-14 CLINICAL STUDY PROTOCOL C25001 AMENDMENT 5 Brentuximab vedotin (SGN-35) A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Protocol Number: C25001 Indication: CD30 Positive Cutaneous T-Cell Lymphoma Phase: 3 Sponsor: Millennium Pharmaceuticals, Inc. EudraCT Number: 2010-024215-14 Therapeutic Area: Oncology Protocol History Original 11 July 2011 Amendment 1 21 December 2011 Amendment 2 24 February 2012 Amendment 3 04 March 2013 Amendment 4 03 July 2013 Amendment 5 02 December 2014 Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, MA USA 02139 Telephone: +1 (617) 679-7000 Approved by: Note: If this document was approved electronically, the electronic approval signatures may be found at the end of the document.
    [Show full text]
  • Role of Denileukin Diftitox in the Treatment of Persistent Or Recurrent Cutaneous T-Cell Lymphoma
    Cancer Management and Research Dovepress open access to scientific and medical research Open Access Full Text Article R EVIEW Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma Frederick Lansigan1 Abstract: Denileukin diftitox (Ontak®) is indicated for the treatment of patients with persistent Diane M Stearns1 or recurrent cutaneous T-cell lymphoma (CTCL), a rare lymphoproliferative disorder of the Francine Foss2 skin. Denileukin diftitox was the first fusion protein toxin approved for the treatment of a human disease. This fusion protein toxin combines the IL2 protein with diphtheria toxin, and targets the 1Hematology/Oncology, Norris Cotton Cancer Center, Dartmouth CD25 subunit of the IL2 receptor, resulting in the unique delivery of a cytocidal agent to CD-25 Hitchcock Medical Center, Lebanon, bearing T-cells. Historically, immunotherapy targeting malignant T-cells including monoclonal 2 NH, USA; Yale Comprehensive antibodies has been largely ineffective as cytocidal agents compared to immunotherapy directed Cancer Center, Yale University School of Medicine, New Haven, CT, USA against B-cells such as rituximab. This review will summarize the development of denileukin diftitox, its proposed mechanism of action, the pivotal clinical trials that led to its FDA approval, For personal use only. the improvements in quality of life, and the common toxicities experienced during the treatment of patients with CTCL. CTCL is often a chronic progressive lymphoma requiring the sequential use of treatments
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • Blueprint Genetics Epidermolysis Bullosa Panel
    Epidermolysis Bullosa Panel Test code: DE0301 Is a 26 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of congenital epidermolysis bullosa. About Epidermolysis Bullosa Epidermolysis bullosa (EB) is a group of inherited diseases that are characterised by blistering lesions on the skin and mucous membranes, most commonly appearing at sites of friction and minor trauma such as the feet and hands. In some subtypes, blisters may also occur on internal organs, such as the oesophagus, stomach and respiratory tract, without any apparent friction. There are 4 major types of EB based on different sites of blister formation within the skin structure: Epidermolysis bullosa simplex (EBS), Junctional epidermolysis bullosa (JEB), Dystrophic epidermolysis bullosa (DEB), and Kindler syndrome (KS). EBS is usually characterized by skin fragility and rarely mucosal epithelia that results in non-scarring blisters caused by mild or no trauma. The four most common subtypes of EBS are: 1) localized EBS (EBS-loc; also known as Weber-Cockayne type), 2) Dowling-Meara type EBS (EBS-DM), 3) other generalized EBS(EBS, gen-nonDM; also known as Koebner type) and 4) EBS-with mottled pigmentation (EBS-MP). Skin biopsy from fresh blister is considered mandatory for diagnostics of generalized forms of EBS. The prevalence of EBS is is estimated to be 1:30,000 - 50,000. EBS-loc is the most prevalent, EBS- DM and EBS-gen-nonDM are rare, and EBS-MP is even rarer. Penetrance is 100% for known KRT5 and KRT14 mutations. Location of the mutations within functional domains of KRT5and KRT14 has shown to predict EBS phenotype.
    [Show full text]
  • WO 2012/139943 A3 18 October 2012 (18.10.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/139943 A3 18 October 2012 (18.10.2012) P O P C T (51) International Patent Classification: Quarry Road East, Bebington, Wirral Merseyside CH63 A61K 8/19 (2006.01) A61K 8/39 (2006.01) 3JW (GB). WIRE, Stephen, Lee [GB/GB]; Unilever R&D A61K 8/27 (2006.01) A61Q 5/06 (2006.01) Port Sunlight, Quarry Road East, Bebington, Wirral Mer A61K 8/368 (2006.01) A61Q 5/10 (2006.01) seyside CH63 3JW (GB). A61K 8/37 (2006.01) (74) Agent: TANSLEY, Sally, Elizabeth; Unilever PLC, Uni (21) International Application Number: lever Patent Group, Colworth House, Sharnbrook, Bedford PCT/EP2012/056152 Bedfordshire MK44 1LQ (GB). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 4 April 2012 (04.04.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (25) Filing Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (26) Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 11162233.8 13 April 201 1 (13.04.201 1) EP MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (71) Applicant (for AE, AG, AU, BB, BH, BW, BZ, CA, CY, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, EG, GB, GD, GH, GM, IE, IL, IN, KE, KN, LC, LK, LS, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, MT, MW, MY, NA, NG, NZ, OM, PG, QA, RW, SC, SD, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]